Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...
Cantor Fitzgerald downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “neutral” from “overweight” and slashed its price target to 70 cents from $5 after the company announced a business update along with financials for...
Cantor Fitzgerald initiated coverage of Clever Leaves Holdings (NASDAQ:CLVR) with an “overweight” rating and $4.50 price target. The stock closed at 92 cents on July 27. “In relative terms, the stock offers better ‘pure...
Cantor Fitzgerald downgraded ObsEva (NASDAQ:OBSV) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company announced a corporate restructuring and refocus of its development and...
Cantor Fitzgerald launched coverage of BioVie (NASDAQ:BIVI) with an “overweight” rating and $7 price target. The stock closed at $2.10 on July 21. BioVie is developing NE3107, an orally bioavailable anti-inflammatory...
Cantor Fitzgerald downgraded Humanigen (NASDAQ:HGEN) to “neutral” from “overweight” and slashed its price target to $2 from $30 after a failed COVID-19 study. The stock closed at $2.99 on July 12. The National Institute...
Cantor Fitzgerald analyst Prakhar Agrawal assumed coverage of Neximmune (NASDAQ:NEXI) with an “overweight” rating and price target of $4. The stock closed at $1.61 on June 29. Neximmune is developing a novel T-cell...
Cantor Fitzgerald upgraded Aurora Cannabis (TSX:ACB) to “overweight” from “neutral” and raised its price target to $4.05 (Canadian) from $3.90. The stock closed at $1.84 on June 23. “We expect Europe, and more...
Cantor Fitzgerald launched coverage of ObsEva (NASDAQ:OBSV) with an “overweight” rating and a 12-month price target of $6. The stock closed at $1.96 on June 2. ObsEva is building a portfolio of best-in-class assets...
Cantor Fitzgerald initiated coverage of Connect Biopharma (NASDAQ:CNTB) with an “overweight” rating and a discounted cash flow-based price target of $5. The stock closed at 75 cents on June 1. “We think that...